Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06253221 · ClinicalTrials.gov registry record · Phase 3

A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

A Phase 3 study of Cardiomyopathy, Hypertrophic, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 3
Development phase
44
Enrollment target
20
Study locations

NCT06253221 is a Phase 3 study of Cardiomyopathy, Hypertrophic that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 44 participants, below the 366-participant average among 6 other Cardiomyopathy, Hypertrophic trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06253221, a Phase 3 study of Cardiomyopathy, Hypertrophic, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
44 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

Conditions Studied

Cardiomyopathy, Hypertrophic

Interventions

  • DRUG Placebo
  • DRUG Mavacamten

Study Locations (20)

California

  • Local Institution - 0032 - Los Angeles
  • Local Institution - 0008 - Los Angeles
  • Local Institution - 0033 - Palo Alto
  • Local Institution - 0044 - San Diego

New York

  • Local Institution - 0010 - New Hyde Park
  • Local Institution - 0024 - New York
  • Local Institution - 0036 - New York
  • Local Institution - 0040 - The Bronx

Alabama

  • Local Institution - 0017 - Birmingham

Arizona

  • Local Institution - 0050 - Phoenix

Colorado

  • Local Institution - 0038 - Aurora

Florida

  • Local Institution - 0031 - St. Petersburg

Georgia

  • Local Institution - 0053 - Atlanta

Illinois

  • Local Institution - 0013 - Chicago

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2024-04-17
Est. Completion 2031-03-28
Phase Phase 3

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06253221

The ClinicalTrials.gov registry entry for NCT06253221 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 366-participant average among 6 other Cardiomyopathy, Hypertrophic trials with a reported enrollment target (88% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiomyopathy, Hypertrophic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06253221 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, New York, Alabama.

Frequently Asked Questions

What is clinical trial NCT06253221 about?

NCT06253221 is a clinical study titled "A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy". The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of mavacamten in adolescent patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM).

What is the current status of trial NCT06253221?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 44 participants. The study started on 2024-04-17. Estimated completion is 2031-03-28.

What conditions does trial NCT06253221 study?

This clinical trial studies the following conditions: Cardiomyopathy, Hypertrophic.

What interventions are being tested in trial NCT06253221?

The interventions under investigation include: Placebo (DRUG), Mavacamten (DRUG).

Who is sponsoring clinical trial NCT06253221?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06253221 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cardiomyopathy, Hypertrophic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cardiomyopathy, Hypertrophic

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.